Overview
Evaluate the Efficacy and Safety of MEDITOXIN in Treatment of Primary Axillary Hyperhidrosis
Status:
Completed
Completed
Trial end date:
2019-09-17
2019-09-17
Target enrollment:
0
0
Participant gender:
All
All
Summary
This study is intented to evaluate the efficacy and safety of MEDITOXIN compared to placebo in treatment of primary axillary hyperhidrosis.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Medy-ToxTreatments:
Botulinum Toxins, Type A
Criteria
Inclusion Criteria:- adult patients aged from 20 to 65, with persistent bilateral primary axillary
hyperhidrosis
Exclusion Criteria:
- those who have secondary hyperhidrosis
- those who have systemic neuromuscular junction disorders
- women who are pregnant or lactating